FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081330990> ?p ?o ?g. }

• W3081330990 endingPage "264" @default.
• W3081330990 startingPage "245" @default.
• W3081330990 abstract "Established tonic-clonic status epilepticus (SE) does not stop in one-third of patients when treated with an intravenous (IV) benzodiazepine bolus followed by a loading dose of a second antiseizure medication (ASM). These patients have refractory status epilepticus (RSE) and a high risk of morbidity and death. For patients with convulsive refractory status epilepticus (CRSE), we sought to determine the strength of evidence for 8 parenteral ASMs used as third-line treatment in stopping clinical CRSE.A structured literature search (MEDLINE, Embase, CENTRAL, CINAHL) was performed to identify original studies on the treatment of CRSE in children and adults using IV brivaracetam, ketamine, lacosamide, levetiracetam (LEV), midazolam (MDZ), pentobarbital (PTB; and thiopental), propofol (PRO), and valproic acid (VPA). Adrenocorticotropic hormone (ACTH), corticosteroids, intravenous immunoglobulin (IVIg), magnesium sulfate, and pyridoxine were added to determine the effectiveness in treating hard-to-control seizures in special circumstances. Studies were evaluated by predefined criteria and were classified by strength of evidence in stopping clinical CRSE (either as the last ASM added or compared to another ASM) according to the 2017 American Academy of Neurology process.No studies exist on the use of ACTH, corticosteroids, or IVIg for the treatment of CRSE. Small series and case reports exist on the use of these agents in the treatment of RSE of suspected immune etiology, severe epileptic encephalopathies, and rare epilepsy syndromes. For adults with CRSE, insufficient evidence exists on the effectiveness of brivaracetam (level U; 4 class IV studies). For children and adults with CRSE, insufficient evidence exists on the effectiveness of ketamine (level U; 25 class IV studies). For children and adults with CRSE, it is possible that lacosamide is effective at stopping RSE (level C; 2 class III, 14 class IV studies). For children with CRSE, insufficient evidence exists that LEV and VPA are equally effective (level U, 1 class III study). For adults with CRSE, insufficient evidence exists to support the effectiveness of LEV (level U; 2 class IV studies). Magnesium sulfate may be effective in the treatment of eclampsia, but there are only case reports of its use for CRSE. For children with CRSE, insufficient evidence exists to support either that MDZ and diazepam infusions are equally effective (level U; 1 class III study) or that MDZ infusion and PTB are equally effective (level U; 1 class III study). For adults with CRSE, insufficient evidence exists to support either that MDZ infusion and PRO are equally effective (level U; 1 class III study) or that low-dose and high-dose MDZ infusions are equally effective (level U; 1 class III study). For children and adults with CRSE, insufficient evidence exists to support that MDZ is effective as the last drug added (level U; 29 class IV studies). For adults with CRSE, insufficient evidence exists to support that PTB and PRO are equally effective (level U; 1 class III study). For adults and children with CRSE, insufficient evidence exists to support that PTB is effective as the last ASM added (level U; 42 class IV studies). For CRSE, insufficient evidence exists to support that PRO is effective as the last ASM used (level U; 26 class IV studies). No pediatric-only studies exist on the use of PRO for CRSE, and many guidelines do not recommend its use in children aged <16 years. Pyridoxine-dependent and pyridoxine-responsive epilepsies should be considered in children presenting between birth and age 3 years with refractory seizures and no imaging lesion or other acquired cause of seizures. For children with CRSE, insufficient evidence exists that VPA and diazepam infusion are equally effective (level U, 1 class III study). No class I to III studies have been reported in adults treated with VPA for CRSE. In comparison, for children and adults with established convulsive SE (ie, not RSE), after an initial benzodiazepine, it is likely that loading doses of LEV 60 mg/kg, VPA 40 mg/kg, and fosphenytoin 20 mg PE/kg are equally effective at stopping SE (level B, 1 class I study).Mostly insufficient evidence exists on the efficacy of stopping clinical CRSE using brivaracetam, lacosamide, LEV, valproate, ketamine, MDZ, PTB, and PRO either as the last ASM or compared to others of these drugs. Adrenocorticotropic hormone, IVIg, corticosteroids, magnesium sulfate, and pyridoxine have been used in special situations but have not been studied for CRSE. For the treatment of established convulsive SE (ie, not RSE), LEV, VPA, and fosphenytoin are likely equally effective, but whether this is also true for CRSE is unknown. Triple-masked, randomized controlled trials are needed to compare the effectiveness of parenteral anesthetizing and nonanesthetizing ASMs in the treatment of CRSE." @default.
• W3081330990 created "2020-09-01" @default.
• W3081330990 creator A5000233437 @default.
• W3081330990 creator A5006656614 @default.
• W3081330990 creator A5024284175 @default.
• W3081330990 creator A5038960596 @default.
• W3081330990 creator A5046645524 @default.
• W3081330990 creator A5048614438 @default.
• W3081330990 creator A5065898901 @default.
• W3081330990 creator A5072757828 @default.
• W3081330990 creator A5074328114 @default.
• W3081330990 creator A5076111271 @default.
• W3081330990 creator A5078444095 @default.
• W3081330990 creator A5083361890 @default.
• W3081330990 creator A5091652039 @default.
• W3081330990 date "2020-08-21" @default.
• W3081330990 modified "2023-10-09" @default.
• W3081330990 title "Treatment of Refractory Convulsive Status Epilepticus: A Comprehensive Review by the American Epilepsy Society Treatments Committee" @default.
• W3081330990 cites W1492512073 @default.
• W3081330990 cites W1526822959 @default.
• W3081330990 cites W1564346238 @default.
• W3081330990 cites W1573800003 @default.
• W3081330990 cites W1803859345 @default.
• W3081330990 cites W1810385029 @default.
• W3081330990 cites W1849128719 @default.
• W3081330990 cites W1856414226 @default.
• W3081330990 cites W1859506634 @default.
• W3081330990 cites W1925921463 @default.
• W3081330990 cites W1964785025 @default.
• W3081330990 cites W1966803129 @default.
• W3081330990 cites W1967417956 @default.
• W3081330990 cites W1972137417 @default.
• W3081330990 cites W1974968449 @default.
• W3081330990 cites W1976010346 @default.
• W3081330990 cites W1976802305 @default.
• W3081330990 cites W1988163197 @default.
• W3081330990 cites W1988358928 @default.
• W3081330990 cites W1988502678 @default.
• W3081330990 cites W1988646373 @default.
• W3081330990 cites W1988774842 @default.
• W3081330990 cites W1992265866 @default.
• W3081330990 cites W1994421931 @default.
• W3081330990 cites W1994862799 @default.
• W3081330990 cites W1997921700 @default.
• W3081330990 cites W1999144748 @default.
• W3081330990 cites W2002358998 @default.
• W3081330990 cites W2003747377 @default.
• W3081330990 cites W2008233442 @default.
• W3081330990 cites W2008452090 @default.
• W3081330990 cites W2008726680 @default.
• W3081330990 cites W2008815426 @default.
• W3081330990 cites W2009160956 @default.
• W3081330990 cites W2010973616 @default.
• W3081330990 cites W2014778415 @default.
• W3081330990 cites W2014810893 @default.
• W3081330990 cites W2014868926 @default.
• W3081330990 cites W2015153817 @default.
• W3081330990 cites W2021351961 @default.
• W3081330990 cites W2022264741 @default.
• W3081330990 cites W2022927468 @default.
• W3081330990 cites W2025589344 @default.
• W3081330990 cites W2026090043 @default.
• W3081330990 cites W2027311472 @default.
• W3081330990 cites W2029569324 @default.
• W3081330990 cites W2032371151 @default.
• W3081330990 cites W2034447252 @default.
• W3081330990 cites W2036467957 @default.
• W3081330990 cites W2037830913 @default.
• W3081330990 cites W2042602590 @default.
• W3081330990 cites W2044020083 @default.
• W3081330990 cites W2045765644 @default.
• W3081330990 cites W2053317796 @default.
• W3081330990 cites W2053977302 @default.
• W3081330990 cites W2055710609 @default.
• W3081330990 cites W2055878985 @default.
• W3081330990 cites W2056360746 @default.
• W3081330990 cites W2062518481 @default.
• W3081330990 cites W2063403233 @default.
• W3081330990 cites W2063505679 @default.
• W3081330990 cites W2063899003 @default.
• W3081330990 cites W2071725069 @default.
• W3081330990 cites W2073069032 @default.
• W3081330990 cites W2073399247 @default.
• W3081330990 cites W2073496453 @default.
• W3081330990 cites W2074979385 @default.
• W3081330990 cites W2075057287 @default.
• W3081330990 cites W2081154155 @default.
• W3081330990 cites W2084468981 @default.
• W3081330990 cites W2086287033 @default.
• W3081330990 cites W2086981442 @default.
• W3081330990 cites W2095163899 @default.
• W3081330990 cites W2095913156 @default.
• W3081330990 cites W2100897048 @default.
• W3081330990 cites W2104047366 @default.
• W3081330990 cites W2114620872 @default.
• W3081330990 cites W2117858464 @default.
• W3081330990 cites W2126973269 @default.
• W3081330990 cites W2129075940 @default.

• next